Q1 FY26 Financial Performance - Revenue increased by 22% to $64,009 million[9] - Gross Margin increased by 22% to $2,319 million[9] - Operating Earnings increased by 18% to $668 million on a GAAP basis, and 37% to $857 million on a non-GAAP basis[9] - Net Earnings attributable to Cardinal Health, Inc increased by 8% to $450 million on a GAAP basis, and 33% to $611 million on a non-GAAP basis[9] - Diluted EPS attributable to Cardinal Health, Inc increased by 11% to $1.88 on a GAAP basis, and 36% to $2.55 on a non-GAAP basis[9] Segment Performance - Pharmaceutical and Specialty Solutions revenue increased by 23% to $59,205 million, with segment profit increasing by 26% to $667 million[11] - Global Medical Products and Distribution revenue increased by 2% to $3,184 million, with segment profit increasing significantly to $46 million[16] - Other (NPHS, at-Home Solutions, and OptiFreight) revenue increased by 38% to $1,641 million, with segment profit increasing by 60% to $166 million[21] FY26 Outlook - Non-GAAP EPS outlook revised upwards to $9.65 - $9.85 from the previous $9.30 to $9.50[29] - Non-GAAP adjusted free cash flow is expected to be $3.0 billion - $3.5 billion, revised upwards from the previous $2.75 billion - $3.25 billion[29] - The company anticipates ~$325 million in Interest and Other expenses[29]

Core Viewpoint - Teva Pharmaceutical Industries Ltd. has released its Q2 2025 Aide Memoire to assist in financial modeling of its quarterly results, reflecting the company's ongoing commitment to delivering medicines globally [2][3]. Company Overview - Teva is a global biopharmaceutical leader with over 120 years of experience, focusing on innovation and the production of generics and biologics [3]. - The company operates in 57 markets with a workforce of 37,000 employees, dedicated to advancing health and addressing patient needs [3].